The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

This study is testing the safety and effectiveness of a new type of immune cell therapy called IBR900 in people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or is not responding to standard treatments. **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of CD20-positive B-cell non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, and others) - Your cancer has come back or stopped responding to treatment that included rituximab or another CD20-targeting drug and an anthracycline-type chemotherapy - You are in reasonably good health and your major organs are functioning adequately **You may NOT be eligible if...** - Your cancer has never been treated with the required prior therapies - Your overall health is too poor to safely receive this therapy - You have conditions that would make you ineligible based on the study's safety criteria Talk to your doctor to see if this trial is right for you.